Combating KRAS^G12C Inhibitor Resistance

To boost KRAS^G12C inhibitor efficacy and counter cancer cells’ ability to mount resistance, combination strategies are being utilized. Findings from the phase III CodeBreaK 300 trial indicate that adding the EGFR inhibitor panitumumab to sotorasib bests standard care for chemorefractory KRAS^G12C colorectal cancer. Joint SHP2 blockade is another approach that shows signs of activity in reversing acquired KRAS^G12C inhibitor resistance, according to preliminary phase I data.